## Giuseppe Vittorio Luigi De Socio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1808545/publications.pdf

Version: 2024-02-01

315719 279778 2,048 117 23 38 citations h-index g-index papers 2702 123 123 123 docs citations all docs times ranked citing authors

#	Article	IF	Citations
1	The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years. BMC Geriatrics, 2018, 18, 99.	2.7	117
2	Impact of Treatment With Protease Inhibitors on Aortic Stiffness in Adult Patients With Human Immunodeficiency Virus Infection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2381-2385.	2.4	92
3	Aortic Stiffness in Untreated Adult Patients With Human Immunodeficiency Virus Infection. Hypertension, 2008, 52, 308-313.	2.7	91
4	Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection. Infectious Diseases, 2020, 52, 698-704.	2.8	78
5	Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infectious Diseases, 2017, 4, ofx239.	0.9	68
6	Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project. Biomedicine and Pharmacotherapy, 2008, $62$ , $6-11$ .	5 <b>.</b> 6	59
7	Prevalence, Awareness, Treatment, and Control Rate of Hypertension in HIV-Infected Patients: The HIV-HY Study. American Journal of Hypertension, 2014, 27, 222-228.	2.0	58
8	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. JAMA Network Open, 2021, 4, e2136246.	5.9	50
9	Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study. Journal of Infection, 2008, 57, 33-40.	3.3	49
10	Factors Associated With Weight Gain in People Treated With Dolutegravir. Open Forum Infectious Diseases, 2020, 7, ofaa195.	0.9	47
11	Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infectious Diseases, 2018, 18, 357.	2.9	42
12	Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort. PLoS ONE, 2016, 11, e0164753.	2.5	41
13	A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48Âweeks' observational data. BMC Infectious Diseases, 2017, 17, 658.	2.9	41
14	Is estimated cardiovascular risk higher in HIV-infected patients than in the general population?. Scandinavian Journal of Infectious Diseases, 2007, 39, 805-812.	1.5	39
15	Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study. Infection, 2016, 44, 589-597.	4.7	39
16	Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data. Annals of Pharmacotherapy, 2018, 52, 740-746.	1.9	36
17	Is Metabolic Syndrome Associated to HIV Infection Per Se? Results from the HERMES Study. Current HIV Research, 2010, 8, 165-171.	0.5	31
18	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	3.0	30

#	Article	IF	CITATIONS
19	Cardiovascular Risk Assessment in Antiretroviral-Na $ ilde{A}$ ve HIV Patients. AIDS Patient Care and STDs, 2009, 23, 809-813.	2,5	29
20	Relations between cardiovascular risk estimates and subclinical atherosclerosis in $na\tilde{A}$ ve HIV patients: results from the HERMES study. International Journal of STD and AIDS, 2010, 21, 267-272.	1.1	29
21	Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study. BMC Infectious Diseases, 2019, 19, 555.	2.9	29
22	Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scandinavian Journal of Infectious Diseases, 2006, 38, 74-75.	1.5	28
23	Metabolic Syndrome: A Real Threat for HIV-Positive Patients?. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 128-131.	2.1	28
24	Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. International Journal of Antimicrobial Agents, 2015, 45, 289-294.	<b>2.</b> 5	24
25	<p>The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile</p> . Drug Design, Development and Therapy, 2020, Volume 14, 5515-5520.	4.3	24
26	Observed versus predicted cardiovascular events and all-cause death in HIV infection: a longitudinal cohort study. BMC Infectious Diseases, 2017, 17, 414.	2.9	23
27	Malignant syphilis with ocular involvement in an HIV–infected patient. International Journal of STD and AIDS, 2011, 22, 298-300.	1.1	22
28	Ageing with HIV: a multidisciplinary review. Infection, 2015, 43, 509-522.	4.7	22
29	Measurement and prediction of antimicrobial resistance in bloodstream infections by ESKAPE pathogens and Escherichia coli. Journal of Global Antimicrobial Resistance, 2019, 19, 154-160.	2.2	22
30	Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients. Journal of Hypertension, 2017, 35, 409-416.	0.5	21
31	Osteonecrosis in human immunodeficiency virus (HIV)-infected patients: a multicentric case–control study. Journal of Bone and Mineral Metabolism, 2011, 29, 383-388.	2.7	20
32	The feature of Metabolic Syndrome in HIV naive patients is not the same of those treated: Results from a prospective study. Biomedicine and Pharmacotherapy, 2012, 66, 348-353.	5 <b>.</b> 6	20
33	Efavirenz and bone health. Aids, 2009, 23, 1181.	2.2	19
34	Negative Influence of HIV Infection on Day-Night Blood Pressure Variability. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 55, 356-360.	2.1	19
35	Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection. Journal of Hypertension, 2013, 31, 560-567.	0.5	19
36	Cerebrospinal fluid penetration of tigecycline. Scandinavian Journal of Infectious Diseases, 2014, 46, 69-72.	1.5	19

#	Article	IF	Citations
37	<p>Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project</p> . Infection and Drug Resistance, 2019, Volume 12, 1385-1391.	2.7	19
38	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. Aids, 2021, 35, 939-945.	2.2	19
39	Delivery in asymptomatic Italian woman with SARS-CoV-2 infection Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020033.	1.3	18
40	Entecavir to treat severe acute hepatitis B. Scandinavian Journal of Infectious Diseases, 2009, 41, 703-704.	1.5	17
41	Salvage Therapy or Simplification of Salvage Regimens with Dolutegravir plus Ritonavir-Boosted Darunavir Dual Therapy in Highly cART-Experienced Subjects: An Italian Cohort. Antiviral Therapy, 2017, 22, 257-262.	1.0	17
42	Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS ONE, 2017, 12, e0179254.	2.5	17
43	Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project. Infection and Drug Resistance, 2018, Volume 11, 615-623.	2.7	17
44	National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study. Infection, 2021, 49, 1033-1038.	4.7	17
45	Severe Acute Hepatitis B Treated with Entecavir. Mediterranean Journal of Hematology and Infectious Diseases, 2011, 3, e2011010.	1.3	16
46	Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project). Biomedicine and Pharmacotherapy, 2013, 67, 293-298.	5.6	16
47	Laboratory automation reduces time to report of positive blood cultures and improves management of patients with bloodstream infection. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2313-2322.	2.9	16
48	Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study. AIDS Patient Care and STDs, 2021, 35, 342-353.	2.5	15
49	Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study. BMC Public Health, 2020, 20, 734.	2.9	15
50	Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012025.	1.3	14
51	Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects. HIV Clinical Trials, 2018, 19, 242-248.	2.0	14
52	Chronological and biological age in HIV infection. Journal of Infection, 2010, 61, 428-430.	3.3	13
53	Adefovir induced hypophosphatemic osteomalacia. Scandinavian Journal of Infectious Diseases, 2011, 43, 990-992.	1.5	13
54	96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience. PLoS ONE, 2012, 7, e39222.	2.5	13

#	Article	IF	CITATIONS
55	Syphilis as a diagnosis of liver abnormalities in HIV. Scandinavian Journal of Infectious Diseases, 2013, 45, 703-705.	1.5	13
56	Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use. AIDS Research and Therapy, 2019, 16, 11.	1.7	13
57	Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study. International Journal of Antimicrobial Agents, 2014, 43, 189-194.	2.5	12
58	Accelerate Phenoâ,,¢ blood culture detection system: a literature review. Future Microbiology, 2020, 15, 1595-1605.	2.0	12
59	Achromobacter denitrificans renal abscess. New Microbiologica, 2012, 35, 245-7.	0.1	12
60	Cholesterol levels in HIV–HCV infected patients treated with lopinavir/r: Results from the SCOLTA project. Biomedicine and Pharmacotherapy, 2008, 62, 16-20.	5.6	11
61	Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides. International Journal of Antimicrobial Agents, 2016, 48, 551-554.	2.5	11
62	Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade. HIV Medicine, 2022, 23, 70-79.	2.2	11
63	An Unusual Case of Epigastric and Back Pain. Circulation: Cardiovascular Imaging, 2013, 6, 1120-1121.	2.6	10
64	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. Aids, 2019, 33, 1256-1260.	2.2	10
65	Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin's lymphoma. International Journal of STD and AIDS, 2008, 19, 715-716.	1.1	9
66	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 338-342.	2.1	9
67	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO―Cohort. PLoS ONE, 2019, 14, e0222225.	2.5	9
68	Fusobacterium nucleatum Endocarditis Mimicking Polymyalgia Rheumatica. Southern Medical Journal, 2009, 102, 1082-1084.	0.7	8
69	Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals. Biomedicine and Pharmacotherapy, 2015, 69, 233-236.	5.6	8
70	Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study. Open Forum Infectious Diseases, 2019, 6, ofz331.	0.9	8
71	Lingual tuberculosis: a rare disease in Western countries. New Microbiologica, 2012, 35, 233-7.	0.1	8
72	Reversibility of Central Nervous System Adverse Events in Course of Art. Viruses, 2022, 14, 1028.	3.3	8

#	Article	IF	CITATIONS
73	HIV Infection and Antiretroviral Treatment: A "Two-Hit" Model for Arterial Stiffness?. American Journal of Hypertension, 2009, 22, 817-818.	2.0	7
74	Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, e76-e79.	1.5	7
75	A study of SARS-CoV-2 epidemiology in Italy: from early days to secondary effects after social distancing. Infectious Diseases, 2020, 52, 866-876.	2.8	7
76	AmBisome administration for Candida albicans shunt infections. Journal of Antimicrobial Chemotherapy, 2003, 52, 1048-1049.	3.0	6
77	Waist circumference and body mass index in HIV infection. HIV Medicine, 2011, 12, 124-125.	2.2	6
78	Monolateral Visual Loss Due To Cryptococcal Meningitis. Journal of the International Association of Providers of AIDS Care, 2011, 10, 76-78.	1.2	6
79	A Giant Pancreatic Pseudocyst in a Patient with HIV Infection. Journal of the International Association of Providers of AIDS Care, 2012, 11, 227-229.	1.2	6
80	Decreasing cardiovascular risk in HIV infection between 2005 and 2011. Aids, 2014, 28, 609-612.	2.2	6
81	Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio?. Aids, 2018, 32, 1083-1084.	2.2	6
82	Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort. AIDS Research and Human Retroviruses, 2020, 36, 19-26.	1.1	6
83	<p>Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort</p> . Infection and Drug Resistance, 2020, Volume 13, 2291-2300.	2.7	6
84	The Use of Nucleoside Reverse Transcriptase Inhibitors Sparing Regimens in Treatment-Experienced HIV-1 Infected Patients. Current HIV Research, 2013, 11, 179-186.	0.5	6
85	Human Papilloma Virus–Associated Lips Verrucous Carcinoma in HIV-Infected Male. Journal of the International Association of Providers of AIDS Care, 2017, 16, 324-326.	1.5	5
86	Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA). AIDS Research and Therapy, 2019, 16, 21.	1.7	5
87	Hepatitis C virus genotypes in the liver and serum of patients with chronic hepatitis C. Clinical Microbiology and Infection, 1996, 2, 20-24.	6.0	4
88	Disseminated tuberculosis and idiopathic CD4+ T-lymphocytopenia. Clinical Microbiology and Infection, 1999, 5, 653-654.	6.0	4
89	Adherence to Antiretroviral Therapy in HIV Patients With Psychiatric Comorbidity. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 1109-1110.	2.1	4
90	Hypertension in HIV patients. Aids, 2006, 20, 1682-1683.	2.2	4

#	Article	IF	CITATIONS
91	Is It Feasible to Impact on Smoking Habits in HIV-Infected Patients? Mission Impossible From the STOPSHIV Project Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 496-503.	2.1	4
92	Accuracy and Impact on Patient Management of New Tools for Diagnosis of Sepsis: Experience with the T2 Magnetic Resonance Bacteria Panel. Pathogens, 2021, 10, 1132.	2.8	4
93	Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians. New Microbiologica, 2017, 40, 139-142.	0.1	4
94	Modelling SARS-CoV-2 unreported cases in Italy: Analysis of serological survey and vaccination scenarios. Infectious Disease Modelling, 2021, 6, 909-923.	1.9	3
95	Diagnosis of Nocardia paucivorans central nervous system infection by DNA sequencing from paraffin-embedded tissue. Infezioni in Medicina, 2016, 24, 147-52.	1.1	3
96	Schizophrenia, Drug Therapy, and Monitoring. New England Journal of Medicine, 2004, 350, 415-416.	27.0	2
97	Antiretroviral Therapy and Adverse Skeletal Effects. Mayo Clinic Proceedings, 2011, 86, 916-917.	3.0	2
98	Effectiveness of first-generation HCV protease inhibitors. European Journal of Gastroenterology and Hepatology, 2016, 28, 37-41.	1.6	2
99	Hypertensive Versus HIV-infected Patients: Who Has the Greatest Target Organ Damage? Comparison of Carotid Plaque Prevalence, Intima Media Thickness and Renal Resistive Index in the Two Groups of Patients. Current Hypertension Reviews, 2018, 14, 48-55.	0.9	2
100	The PARTIAL ACHIEVEMENT OF THE 90-90-90 UNAIDS TARGET IN A COHORT OF HIV INFECTED PATIENTS FROM CENTRAL ITALY Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020017.	1.3	2
101	Improving the etiological diagnosis of osteoarticular infections with the commercial multiplex real-time polymerase chain reaction SeptiFast $\hat{A}^{\circ}$ . Diagnostic Microbiology and Infectious Disease, 2020, 97, 115002.	1.8	2
102	Late onset opportunistic infections in a renal allograft recipient: a case report. Infezioni in Medicina, 2004, 12, 136-8.	1.1	2
103	Accelerate Phenoâ,, \$\psi\$ system in sepsis by Gram-negative pathogens: four months of hospital experience. New Microbiologica, 2020, 43, 6-12.	0.1	2
104	HIV, pressure wave reflections, and arterial stiffness: It's a matter of time. Artery Research, 2009, 3, 100.	0.6	1
105	Tuberculosis after gastrectomy, plasmatic concentration of antitubercular drugs. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012007.	1.3	1
106	Low frequency of skin reactions in a cohort of patients on raltegravir. Journal of Antimicrobial Chemotherapy, 2012, 67, 1800-1802.	3.0	1
107	Evaluation of IVD 3.0 Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium tuberculosis and nontuberculous mycobacteria and its use in routine diagnostics. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2027-2029.	2.9	1
108	Efficacy of 1998 Vs 2006 First-Line Antiretroviral Regimens for HIV Infection: An Ordinary Clinics Retrospective Investigation. Journal of Antivirals & Antiretrovirals, 2012, 04, .	0.1	1

#	Article	IF	CITATIONS
109	Acute Cytomegalovirus Meningomyelitis in an Immunocompetent Patient. European Journal of Clinical Microbiology and Infectious Diseases, 1998, 17, 885-887.	2.9	0
110	Sepsis with multiple organ disfunction. Lancet, The, 1998, 351, 1552.	13.7	0
111	Acute Meningoencephalitis in Chronic HIV Infection: Clinical Resolution with Lopinavirâ€Ritonavir–Containing Therapy. Clinical Infectious Diseases, 2008, 46, 1938-1938.	5.8	0
112	Use of quantitative ultrasound as bone mineral density evaluation in an Italian female population living with HIV: A real-life experience. Journal of Women and Aging, 2019, 31, 176-188.	1.0	0
113	Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse. Aids, 2021, 35, 1708-1710.	2.2	0
114	Comments on "Realâ€world reâ€treatment outcomes of directâ€acting antiviral therapy failure in patients with chronic hepatitis Câ€. Journal of Medical Virology, 2022, 94, 436-438.	5.0	0
115	Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort. PLoS ONE, 2021, 16, e0258533.	2.5	0
116	Organ Damage in HIV-Positive Patients with High Blood Pressure. Journal of AIDS & Clinical Research, 2013, 4, .	0.5	0
117	SLAM Project - Second-Level Diagnostic Assessment: Multidisciplinary approach to HIV Patients. New Microbiologica, 2019, 42, 150-155.	0.1	0